Advertisement


Hans Wildiers, MD, PhD on the TH3RESA Study: Final OS Results

2015 San Antonio Breast Cancer Symposium

Advertisement

Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).



Related Videos

Breast Cancer

Harold J. Burstein, MD, PhD, on Results of the CREATE-X Clinical Trial on Higher-Risk Disease

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses the CREATE-X adjuvant study of capecitabine in high-risk patients with residual disease (Abstract S6-01).

Breast Cancer

Andrew Seidman, MD, and Sabine Seisling, PhD, on Early-Stage Breast Cancer Outcomes: Breast-Conserving Therapy vs Mastectomy

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Sabine Siesling, PhD, of the Netherlands Comprehensive Cancer Organization, discuss the improved overall survival after 10 years in women who received breast-conserving surgery compared with those who received mastectomy with radiation treatment. (Abstract S3-05)

Breast Cancer

Andrew Seidman, MD, and Seema Khan, MD, MPH on Controversies in the Management of DCIS

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discuss the session moderated by Dr. Khan on this important topic (Session ES8).

Breast Cancer

Gunter von Minckwitz, MD: Early Survival Analysis of GeparSixto

Gunter von Minckwitz, MD, of the German Breast Group, discusses data from this phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (Abstract S2-05).

Breast Cancer

Andrew Seidman, MD, and Eric Winer, MD, on Triple-Negative Breast Cancer: Results of the CALGB Alliance Trial

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Eric P. Winer, MD, of the Dana-Farber Cancer Institute, discuss the results of this study that showed pathologic complete response to presurgery chemotherapy improved survival (Abstract S2-05).

Advertisement

Advertisement




Advertisement